Engineered Cryo‐Shocked Cancer Cells Deliver Dual‐Function Gene Medicines for Melanoma Immunotherapy
Advanced Materials · 2026
DOI: 10.1002/adma.202515441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Yali Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory of Biomedical Analytics, Chongqing Science and Technology Commission, College of Pharmaceutical Sciences, Southwest Universi…. Hauptthemen laut MEDLINE: Immunotherapy, Melanoma. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chongqing Talents Program for Outstanding Scientists, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Immunotherapies for melanoma are frequently hindered by resistance to immune checkpoint blockade and poor infiltration of T cells into the tumor microenvironment (TME). To overcome these limitations, a novel dual‐function plasmid is designed, termed CXCL9‐ABE PCSK9 , that combines adenine base editing to knock down PCSK9 (a newly identified immunosuppressive factor that impairs CD8⁺ T cell activity) with overexpression of the chemokine CXCL9, known for its role in recruiting T cells. The plasmid is first encapsulated into a liposome and then loaded on the liquid nitrogen‐treated (LNT) tumor cells, generating LNT@LipoC9AP particles. These LNT cells maintain structural integrity and tumor‐homing properties, functioning as a “Trojan horse” delivery system, while losing pathogenicity. It is find that LNT@LipoC9AP effectively increased CD8 + T cell tumor infiltration and exhibited potent antitumor effects in vitro and in vivo. To further improve tumor targeting, LNT@LipoC9AP is engineered by decorating the LNT cell surface with RGD4C peptides, yielding R‐LNT@LipoC9AP, which targets αvβ3 integrins commonly overexpressed in melanoma. R‐LNT@LipoC9AP demonstrated superior tumor accumulation, enhanced therapeutic efficacy, and a favorable safety profile. Altogether, the LNT cell‐based co‐delivery system for CXCL9 and ABE PCSK9 overcomes the limitations of current tumor immunotherapy and may serve as a promising gene therapy strategy for solid tumors treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chongqing Key Laboratory of Biomedical Analytics, Chongqing Science and Technology Commission, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China.
- Department of Pharmacy, The Second Affiliated Hospital, Army Medical University, 83 Xinqiao Road, Shapingba, Chongqing, 400037, China.
ORCID-Profile: Cheng Zhi Huang
Förderung
- National Natural Science Foundation of China
- Chongqing Talents Program for Outstanding Scientists
- Fundamental Research Funds for the Central Universities
- Chongqing Bayu Scholar Program - Young Scholar
Zitieren
APA
Liu, Y., Hu, C., Huang, J., Lai, W., Zhou, H., Zhang, Q., Li, G., & Huang, C. Z. (2026). Engineered Cryo‐Shocked Cancer Cells Deliver Dual‐Function Gene Medicines for Melanoma Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202515441
Vancouver
Liu Y, Hu C, Huang J, Lai W, Zhou H, Zhang Q, et al. Engineered Cryo‐Shocked Cancer Cells Deliver Dual‐Function Gene Medicines for Melanoma Immunotherapy. Advanced Materials. 2026. doi:10.1002/adma.202515441
BibTeX
@article{Liu2026,
author = {Liu, Yali and Hu, Changpeng and Huang, Jingtao and Lai, Wenjing and Zhou, Huyue and Zhang, Qian and Li, Guobing and Huang, Cheng Zhi},
title = {Engineered Cryo‐Shocked Cancer Cells Deliver Dual‐Function Gene Medicines for Melanoma Immunotherapy},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202515441}
}
EUVIMED